CN109182435A - 一种生物源二肽基肽酶-iv抑制剂的制备方法 - Google Patents
一种生物源二肽基肽酶-iv抑制剂的制备方法 Download PDFInfo
- Publication number
- CN109182435A CN109182435A CN201811237254.XA CN201811237254A CN109182435A CN 109182435 A CN109182435 A CN 109182435A CN 201811237254 A CN201811237254 A CN 201811237254A CN 109182435 A CN109182435 A CN 109182435A
- Authority
- CN
- China
- Prior art keywords
- fish
- dipeptidyl peptidase
- skin
- collagen
- japanese croaker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title claims abstract description 16
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241000480037 Argyrosomus japonicus Species 0.000 claims abstract description 47
- 102000008186 Collagen Human genes 0.000 claims abstract description 39
- 108010035532 Collagen Proteins 0.000 claims abstract description 39
- 229920001436 collagen Polymers 0.000 claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 31
- 241000251468 Actinopterygii Species 0.000 claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 17
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims abstract description 11
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims abstract description 6
- 108090000790 Enzymes Proteins 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000003513 alkali Substances 0.000 claims description 14
- 239000004365 Protease Substances 0.000 claims description 13
- 239000002608 ionic liquid Substances 0.000 claims description 13
- 108090000526 Papain Proteins 0.000 claims description 12
- 235000019834 papain Nutrition 0.000 claims description 12
- 229940055729 papain Drugs 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000057297 Pepsin A Human genes 0.000 claims description 10
- 108090000284 Pepsin A Proteins 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- 229940111202 pepsin Drugs 0.000 claims description 10
- 238000005238 degreasing Methods 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229940088598 enzyme Drugs 0.000 claims description 5
- 230000002779 inactivation Effects 0.000 claims description 5
- 230000036961 partial effect Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 238000005286 illumination Methods 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract description 9
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract description 5
- 239000006227 byproduct Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000002058 anti-hyperglycaemic effect Effects 0.000 abstract description 2
- 238000000751 protein extraction Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 7
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 6
- 102100040918 Pro-glucagon Human genes 0.000 description 6
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- -1 imidazoles sodium hydroxides Chemical class 0.000 description 3
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 3
- 239000000859 incretin Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811237254.XA CN109182435B (zh) | 2018-10-23 | 2018-10-23 | 一种生物源二肽基肽酶-iv抑制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811237254.XA CN109182435B (zh) | 2018-10-23 | 2018-10-23 | 一种生物源二肽基肽酶-iv抑制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109182435A true CN109182435A (zh) | 2019-01-11 |
CN109182435B CN109182435B (zh) | 2021-12-17 |
Family
ID=64942868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811237254.XA Active CN109182435B (zh) | 2018-10-23 | 2018-10-23 | 一种生物源二肽基肽酶-iv抑制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109182435B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109776652A (zh) * | 2019-01-30 | 2019-05-21 | 浙江省医学科学院 | 鳕鱼皮寡肽及其分离纯化方法和在制备ɑ-葡萄糖苷酶抑制剂及抗Ⅱ型糖尿病药物中的应用 |
CN114957450A (zh) * | 2022-05-31 | 2022-08-30 | 甘肃农业大学 | 胶原基dpp-iv抑制肽的制备方法及胶原基dpp-iv抑制肽 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104177493A (zh) * | 2014-03-24 | 2014-12-03 | 南京工业大学 | 一种以双阳离子型离子液体为溶剂快速制备再生胶原蛋白的方法 |
CN107164445A (zh) * | 2017-06-08 | 2017-09-15 | 中国农业大学 | 具有dpp‑ⅳ抑制功能的鱼皮蛋白肽及其制备方法与应用 |
CN107586818A (zh) * | 2017-09-11 | 2018-01-16 | 浙江海洋大学 | 一种日本黄姑鱼鱼皮胶原蛋白的提取方法及应用 |
-
2018
- 2018-10-23 CN CN201811237254.XA patent/CN109182435B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104177493A (zh) * | 2014-03-24 | 2014-12-03 | 南京工业大学 | 一种以双阳离子型离子液体为溶剂快速制备再生胶原蛋白的方法 |
CN107164445A (zh) * | 2017-06-08 | 2017-09-15 | 中国农业大学 | 具有dpp‑ⅳ抑制功能的鱼皮蛋白肽及其制备方法与应用 |
CN107586818A (zh) * | 2017-09-11 | 2018-01-16 | 浙江海洋大学 | 一种日本黄姑鱼鱼皮胶原蛋白的提取方法及应用 |
Non-Patent Citations (4)
Title |
---|
CHEUNG等: "Enzymatic production of protein hydrolysates from steelhead (Oncorhynchus mykiss) skin gelatin as inhibitors of dipeptidyl-peptidase IV and angiotensin-I converting enzyme", 《JOURNAL OF FUNCTIONAL FOODS》 * |
TSUYOSHI SHIMOBOJI等: "Photoresponsive polymer-enzyme switches", 《PNAS》 * |
姚文惠: "聚乙二醇功能化离子液体的相行为调控及其在环加成反应和蛋白质分离中的应用", 《中国博士学位论文全文数据库 工程科技Ⅰ辑》 * |
贺江等: "草鱼鱼鳞胶原蛋白提取及活性肽制备研究", 《食品研究与开发》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109776652A (zh) * | 2019-01-30 | 2019-05-21 | 浙江省医学科学院 | 鳕鱼皮寡肽及其分离纯化方法和在制备ɑ-葡萄糖苷酶抑制剂及抗Ⅱ型糖尿病药物中的应用 |
CN109776652B (zh) * | 2019-01-30 | 2020-08-18 | 浙江省医学科学院 | 鳕鱼皮寡肽及其分离纯化方法和在制备ɑ-葡萄糖苷酶抑制剂及抗Ⅱ型糖尿病药物中的应用 |
CN114957450A (zh) * | 2022-05-31 | 2022-08-30 | 甘肃农业大学 | 胶原基dpp-iv抑制肽的制备方法及胶原基dpp-iv抑制肽 |
CN114957450B (zh) * | 2022-05-31 | 2023-09-22 | 甘肃农业大学 | 胶原基dpp-iv抑制肽的制备方法及胶原基dpp-iv抑制肽 |
Also Published As
Publication number | Publication date |
---|---|
CN109182435B (zh) | 2021-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Andreassen et al. | Screening of by-products from the food industry as growth promoting agents in serum-free media for skeletal muscle cell culture | |
CN108796017B (zh) | 牛骨肽及其酶解提取方法 | |
WO2020143205A1 (zh) | 一种利用废弃羽毛生产氨基酸液肥的生物制方法 | |
CN106519020A (zh) | 一种具有美容功效的功能性肽及其制备方法和用途 | |
AU2010264800B2 (en) | Compositions for treating degenerative joint diseases | |
CN109182435A (zh) | 一种生物源二肽基肽酶-iv抑制剂的制备方法 | |
CN108822230B (zh) | 一种超声提取刺梨果渣的多糖 | |
CN105273081B (zh) | 一种二肽基肽酶iv抑制肽及其制备和应用 | |
Espinales et al. | Collagen, protein hydrolysates and chitin from by-products of fish and shellfish: An overview | |
CN108935912B (zh) | 一种具有dpp-ⅳ抑制和抗疲劳功能的鱼肉蛋白肽及其制备方法 | |
CN103169942A (zh) | 一种制备鹿茸胶原蛋白的酶解方法 | |
Cao et al. | Release principle of peptides and amino acids during the autolysis of shrimp head from Litopenaeus vannamei after UV‐C irradiation stress | |
CN109295140A (zh) | 一种日本黄姑鱼鱼鳔胶原蛋白源二肽基肽酶-iv抑制肽的制备方法 | |
Zhu et al. | Optimization of ultrasonic-assisted enzymatic hydrolysis to extract soluble substances from edible fungi by-products | |
CN103243015B (zh) | 一种具有抗氧化养生功能的食醋及其制备方法 | |
CN106367461A (zh) | 一种从猪皮中提取低分子量活性胶原蛋白肽的方法 | |
CN110923285A (zh) | 牛骨肽及其制备工艺 | |
CN102936611B (zh) | 一种从带鳞黑鲽鱼皮中提取的胶原及其应用 | |
Harris et al. | Developments for collagen hydrolysate in biological, biochemical, and biomedical domains: A comprehensive review | |
KR100906170B1 (ko) | 초음파를 이용한 굴 미백 활성 펩타이드 제조방법 | |
Tan et al. | Phytochemicals derived from soya bean husk exert hypoglycemic and anti-adipogenic properties in cell culture models | |
CN108250291A (zh) | 一种抗氧化骨胶原多肽及其制备方法 | |
CN110800858B (zh) | 一种鲟鱼蛋白肽粉及其制备方法与应用 | |
CN108893512B (zh) | 一种具有dpp-ⅳ抑制和抗疲劳功能的蜂蛹蛋白肽及其制备方法 | |
CN112245452A (zh) | 一种骨提取物的制备方法及对骨质疏松和骨关节炎的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Han Tao Inventor after: Tang Yunping Inventor after: Jiang Xiaoxia Inventor after: Ding Guofang Inventor after: Yu Fangmiao Inventor after: Yang Zuisu Inventor after: Huang Fangfang Inventor after: Chen Yan Inventor before: Tang Yunping Inventor before: Jiang Xiaoxia Inventor before: Ding Guofang Inventor before: Yu Fangmiao Inventor before: Yang Zuisu Inventor before: Huang Fangfang Inventor before: Chen Yan |